IMUGENE LIMITED

IMU
End-of-day quote. End-of-day quote  - 10/19
0.45AUD +8.43%
Prev.0.4150
Open0.4250
High0.4520
Low0.4100
Volume19 701 180
Latest news
09/22
09/20
09/20
09/20
Chart IMUGENE LIMITED
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBullishBullish
Resistance0,500,500,48
Spread/Res.-9,1%-9,1%-6,3%
Spread/Supp.17%58%114%
Support0,390,290,21
Financials
Sales 2022 13,5 M 10,1 M 10,1 M
Net income 2022 -24,9 M -18,6 M -18,6 M
Net Debt 2022 - - -
P/E ratio 2022 -96,8x
Yield 2022 -
Capitalization 2 473 M 1 849 M 1 850 M
Capi. / Sales 2022 183x
Capi. / Sales 2023 156x
Nbr of Employees 5
Free-Float 90,8%
Company
Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against...

>> Read more
Sector :
Other Biotechnology & Medical Research
Calendar :
2022-03-02 Earnings Release

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,45 AUD
Average target price 0,48 AUD
Spread / Average Target 5,56%